Company / Working Capital
Esperion Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$161.8M
FY2025
5-year range
$44.8M / $255.6M
FY2021-FY2025
Trend
+76.3%
vs FY2024
Sector context
#180 of 213
Health Care
What the data says
Esperion Therapeutics, Inc.'s working capital of $162M is lower than 85% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 10 years, ranging from $45M in FY2023 to $256M in FY2021.
Based on SEC 10-K filings.
$162M in FY2025 with a 5-year CAGR of -8.5%.
Improved from $45M to $162M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +1.6%
- 5-Year CAGR
- -8.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 213This company $161.8M Sector average $934.6M
▼
-82.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -8.5%, indicating a declining trend.
- In FY2025, working capital increased 76.3% year-over-year.
- Ranks #180 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $161.8M | +76.3% |
| FY2024 | $91.8M | +104.6% |
| FY2023 | $44.8M | -71.0% |
| FY2022 | $154.4M | -39.6% |
| FY2021 | $255.6M | +1.5% |
| FY2020 | $251.8M | +72.9% |
| FY2019 | $145.6M | +86.0% |
| FY2018 | $78.3M | -54.2% |
| FY2017 | $170.8M | -13.7% |
| FY2016 | $198.0M | -5.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026